Herb-Pharma AG at CPHI Frankfurt 2025: four medical brands, strong interest in the MDR portfolio, and new partnerships in global markets.
Herb-Pharma AG (Zurich) participated in the prestigious CPHI Frankfurt 2025 trade fair, where leading manufacturers of medical devices and pharmaceutical solutions from around the world gathered. Participating among nearly 2,400 exhibitors was an opportunity to confirm our place among respected expert brands built on clinical value, quality, and trust.
Why Our Participation Was Important
Professional visitors showed significant interest in portfolios with proven efficacy and MDR certification. This represents one of the EU’s strictest regulatory standards, requiring clinical data, thorough safety documentation, years of preparation, and ongoing audits. Not every medical device manufacturer meets these criteria, which is why discussions about our MDR portfolio were often one of the first topics visitors raised.
Our Portfolio at CPHI
Herb-Pharma presented a portfolio of four key brands that have built trust in European and international markets:
- VIROSTOP – a leader in protecting the upper respiratory tract from viruses; particularly effective for flu and colds.
- GYNTIMA – a natural biological solution for restoring and maintaining long-term intimate health for women of all ages.
- HEMORRELAX – a modern approach to anorectal care for hemorrhoids, featuring a botox-like effect in a cream and suppositories for relief and regeneration.
- AURECON – complete natural ear care for the whole family, from prevention to relief.
What CPHI Brought Us
CPHI resulted in numerous valuable meetings with partners from Europe, the USA, South America, Asia, and the Middle East. Discussions were dominated by the topics of MDR certification and the clinical value of medical devices, confirming the growing demand for regulated and trustworthy solutions. Interest in distributing our portfolio outside the EU was evident, and feedback on our planned innovations for 2025–2026 provided us with valuable direction.
The second day of the exhibition brought the most in-depth professional conversations – after the initial “getting to know you” phase, visitors returned with specific questions and an interest in collaboration.
A View from the Booth
The greatest attention was drawn to VIROSTOP – experts were interested in what distinguishes it from common flu and cold preparations. Discussions focused mainly on its clinically confirmed mechanism of action based on polyphenols, as well as upcoming innovations in the brand’s portfolio.
HEMORRELAX, in the form of rectal suppositories and a cream for hemorrhoids, also received high praise, thanks to its biotechnological botox-like effect.
We were pleasantly surprised by the high level of interest in GYNTIMA vaginal suppositories – visitors appreciated their natural biological effect and the fact that the four variants can specifically address women’s intimate issues at different stages and situations of life.
What’s Next
CPHI confirmed that the direction we are heading – professional solutions, clinical value, and MDR quality – has its place in the global market. The contacts we made and the feedback from the exhibition are an impetus for us to continue innovating and strengthening our brands on the international stage.
